

Our ref: IG/FOI/24.R.230

19 June 2024

Sent via email to: [REDACTED]

Dear [REDACTED]

Request under the Freedom of Information Act 2000

I write further to your request for information, which was received on 3 June 2024, to confirm, in accordance with S.1(1)(a) of the Freedom of Information Act 2000, that Powys Teaching Health Board (PTHB) does not hold the information that you require.

For ease of reference your request is set out below and my response follows.

Your Freedom of Information (FOI) Request:

I am researching the incidence and treatment of breast cancer. I would greatly appreciate if you could answer the following questions

Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:

- Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)
- Abemaciclib + Fulvestrant
- Alpelisib + Fulvestrant
- Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide
- Aromatase Inhibitor as a single agent
- Atezolizumab
- Capecitabine as a single agent
- Carboplatin + Paclitaxel
- Eribulin as a single agent or in combination
- Everolimus + Exemestane
- Fulvestrant as a single agent
- Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)
- Palbociclib + Fulvestrant
- Parp Inhibitors (Olaparib/Talazoparib)

- Pembrolizumab
- Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)
- Ribociclib + Fulvestrant
- Sacituzumab Govitecan
- Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent
- Transtuzumab deruxtecan
- Trastuzumab as a single agent or in combination
- Trastuzumab emtansine
- Any other active systemic anti-cancer therapy

Q2. If breast cancer is not treated at or within the Health Board, where are patients referred?

Powys Response:

I can confirm this information is not held by the health board. Powys Teaching Health Board (PTHB) does not initiate or continue treatment with the medicines included in your FOI request. Any patients requiring access to these medicines would be referred to and treated by specialist providers outside Powys. We therefore recommend that you approach them directly for this information via the details below:

Health Trust/ Organisation	FOI Contact Details
Gloucester Hospitals NHS Foundation Trust	ghn-tr.foi@nhs.net
Shrewsbury & Telford Hospital NHS Trust	https://www.sath.nhs.uk/about-us/freedom-of-information/make-an-enquiry/
The Royal Wolverhampton NHS Trust	rwh-tr.foi@nhs.net
Wye Valley NHS Trust	https://www.wyevalley.nhs.uk/about-us/information-requests.aspx

Health Board/ Organisation	FOI Contact Details
Aneurin Bevan University Health Board	FOI.ABB@wales.nhs.uk
Betsi Cadwaladr University Health Board	bcu.foi@wales.nhs.uk
Cardiff & Vale University Health Board	FOI.Requests@wales.nhs.uk
Cwm Taf Morgannwg University Health Board	Freedomofinformation@wales.nhs.uk
Hywel Dda University Health Board	FOI.hyweldda@wales.nhs.uk
Swansea Bay University Health Board	FOIA.Requests@wales.nhs.uk
Velindre University Health Board	Foi.vunhst@wales.nhs.uk

Under the terms of the Health Board's Freedom of Information procedure, individuals seeking access to recorded information held by the Health Board are entitled to request an internal review of the handling of their requests. If you would like to complain about the Health Board's handling of your request, please contact us directly at the address below or register your complaint via powysfoi.foi@wales.nhs.uk

If after Internal Review you remain dissatisfied you are also entitled to refer the matter to the information commissioner at the Information Commissioner's

Office (Wales), 2nd Floor, Churchill House, Churchill Way, Cardiff, CF10 2HH.
Telephone Number: 0330 414 6421.

Yours sincerely

A handwritten signature in black ink that reads "KL Wright". The signature is written in a cursive style with a horizontal line underneath the name.

Kate Wright
Medical Director

Rydym yn croesawu derbyn gohebiaeth yng Nghymraeg. Byddwn yn ateb y fath ohebiaeth yng Nghymraeg ac ni fydd hyn yn arwain at oedi.

We welcome receiving correspondence in Welsh. We will reply to such correspondence in Welsh and this will not lead to a delay.